Myriad, AbbVie expand research collaboration, 5/16
May 2016—Myriad Genetics announced an expanded companion diagnostics research collaboration with AbbVie to support the development of AbbVie’s investigational PARP inhibitor, veliparib.
Webinars and Sponsored Roundtables — Register Now
Tuesday, November 10, 2026, 1:00 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.
Webinar presenter Samuel Caughron, MD, FCAP, Chief Strategy Officer, MAWD Pathology, Medical Director of Laboratory, AdventHealth Kansas City, Medical Director of Laboratory, Labcorp, President, Member & Director, Pathology Ventures, LLC
CAP TODAY does not endorse any of the products or services named within. This program is intended for US healthcare professionals. This program is being sponsored by AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, November 18, 2026, 12:00 PM-1 PM ET
Join leading pathology experts, Savitri Krishnamurthy, MD, and Marilyn Bui, MD, PhD, for a webinar exploring potential challenges in HER2 IHC testing for breast cancer, emerging evidence supporting digital and computational pathology as assistive tools for pathologists in HER2 IHC assessment, and practical considerations for real-world implementation and adoption.
Webinar presenters Savitri Krishnamurthy, MD, Professor of Pathology, Department of Anatomical Pathology The University of Texas MD Anderson Cancer Center, Houston, Texas, and Marilyn Bui, MD, PhD, Surgical Pathologist and Cytopathologist Member and Professor, Departments of Pathology, Machine Learning, and Translational Pathology, Scientific Director, Analytic Microscopy Core Chair, Women in Oncology Executive Board Moffitt Cancer Center, Tampa, Florida
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speakers are being compensated for their presentations. The program is not CME accredited and may not be used for CME credit.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, December 9, 2026, 12 PM-1 PM ET
Hear an expert pathologist discuss the role of HER2 IHC testing and scoring in solid tumors including endometrial, ovarian, cervical, bladder, non-small cell lung, colorectal, and biliary cancers
Webinar presenter Michelle Shiller, DO, MSPT, Baylor Sammons Cancer Center; Fulgent Genetics; Texas Cancer Interception Institute
CAP TODAY does not endorse any of the products or services named within. This program is intended for US healthcare professionals. This program is being sponsored by AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Subspecialties
Interactive Product Guides
Marketplace
Digital pathology scanner, 5/16
May 2016—Leica Biosystems introduced the Aperio Versa, a combination digital pathology research scanner for bright-field, fluorescence, and FISH imaging. High levels of automation and an optional 200-slide autoloader enable unsupervised batch processing, from low magnification to high resolution, oil-immersion scanning.
Next-generation molecular diagnostics prototype, 5/16
May 2016—Abbott demonstrated a prototype of the company’s next-generation molecular diagnostics platform at a recent scientific event hosted for its customers. The new system is currently being designed from the ground up based on extensive input from laboratory customers.
Multiplex Staph blood culture panel cleared, 5/16
May 2016—Great Basin Scientific has received FDA clearance for its Staph ID/R Blood Culture Panel. The panel is a sample-to-result, automated, DNA multiplex assay for simultaneous identification of Staphylococcus aureus and Staphylococcus species directly from positive blood cultures.
Sarstedt acquires division of m-u-t GmbH, 5/16
May 2016—The Sarstedt Group has acquired the laboratory automation business of m-u-t GmbH, headquartered in Wedel, Germany, and its direct customer business worldwide.
Horizon, Centauri form joint venture, 5/16
May 2016—Horizon Discovery Group has formed an immuno-oncology joint venture, Avvinity Therapeutics, with Centauri Therapeutics, a U.K.-based biotechnology company focused on the discovery and development of novel molecules targeting life-threatening infectious diseases.
CTC recovery kits, 5/16
May 2016—Fluxion Biosciences has launched two kits for enhanced circulating tumor cell isolation and recovery that are designed to work exclusively with the IsoFlux Liquid Biopsy system.
Affymetrix receives grant, 5/16
May 2016—With a grant from Innovate UK, Affymetrix will develop a health and economic benefits assessment for replacing surveillance cystoscopies with noninvasive genomic profiling from urinary cell-free DNA using the OncoScan FFPE Assay Kit.
Collaboration to validate Zika virus detection panel, 5/16
May 2016—Luminex is collaborating with the Laboratory of Molecular Evolution and Bioinformatics, Biomedical Sciences Institute, University of São Paulo, Brazil, to validate a multianalyte Zika virus assay developed by Luminex partner GenArraytion.
FDA-cleared RPR test system, 5/16
May 2016—Gold Standard Diagnostics announced FDA 510(k) clearance of its AIX1000 Rapid Plasma Reagin Automated Test System for syphilis testing.